Montelukast / Levocetirizine
Therapeutic agent (verify pharmacological class)
What it is used for
Therapeutic use is agent- and indication-specific within the class (Therapeutic agent (verify pharmacological class)). Use according to culture results, national guidelines (Kenya STG/EML where applicable) and the current product SmPC. Allergic rhinitis
Warnings
[From component Montelukast] Monitoring of patient when systemic corticosteroid reduction is considered. Combination therapy with bronchodilator. Exercise-induced asthma. Pregnancy and lactation
Possible side effects
[From component Montelukast] Dream abnormalities, hallucinations, palpitations, drowsiness, irritability, restlessness, insomnia, increased sweating, headache; nausea, vomiting, dyspepsia, diarrhea, abdominal pain; myalgia including muscle cramps; increased bleeding tendency, bruising edema; tremor, dry mouth, vertigo, arthralgia.
Storage
Store as labelled. Keep out of reach of children.
No reviewed patient-education article is available. The fields shown are from the currently verified medicine record and unavailable fields are not inferred.